Phase 1 Friedreich Ataxia Trial, Not Yet Recruiting NCT06772870 Sponsor: Design Therapeutics, Inc. Condition: Friedreich Ataxia
Back to Friedreich Ataxia

Phase 1 Friedreich Ataxia Trial, Not Yet Recruiting

NCT06772870
Not Yet Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be between 18 and 45 years old at the time you sign the consent form.
  • You must be generally healthy, based on a medical check-up that includes your health history, a physical exam, blood/lab tests, and a heart tracing (ECG).
  • You must agree to avoid intense or strenuous exercise beyond your normal daily activity for the duration of the study.
  • Your body mass index (BMI) must be between 16 and 32, and you must weigh 100 kg (about 220 lbs) or less at your screening visit.
  • If you are male or female and able to have children, you must agree to use an approved form of contraception as required by the study rules.
  • You must be able to understand and sign a consent form agreeing to take part in the study.

Who may not be able to join:

  • You may not be eligible if you have any ongoing medical condition that the study doctor believes could put you at risk or prevent you from completing the study.
  • You may not be eligible if you have any significant non-medical or mental health conditions that could put you at higher risk, affect your ability to participate, or make it harder to interpret your results (confirm with trial site).
  • You may not be eligible if you are unwilling to follow the contraception requirements set out by the study for its full duration.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ofer Gronen, MD, Nucleus Network

Phone: +1 858-293-4902

Australian sites

Nucleus Network, Level 5, 89 Commercial Road, Melbourne, Victoria
+61 1300 715 787

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 1
Sponsor
Design Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
1 February 2025
Est. completion
1 September 2025

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Frequency of treatment emergent adverse events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov